Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Shockwaves as FDA Vaccine Chief Resigns in April Amidst Controversial Decisions: A Turning Point in Public Health
News

Shockwaves as FDA Vaccine Chief Resigns in April Amidst Controversial Decisions: A Turning Point in Public Health

By adminitfy
March 7, 2026 2 Min Read

Vinay Prasad, a significant figure at the U.S. Food and Drug Administration (FDA) overseeing vaccines and biotechnology, will resign from his position at the end of April. This announcement comes amidst growing concerns and criticism regarding the FDA’s recent decisions within the biotech and pharmaceutical sectors. An agency representative confirmed Prasad’s exit, marking his second departure from the role; he briefly left the position in July due to backlash over regulatory choices but returned just two weeks later.

FDA Commissioner Marty Makary shared on X that a successor for Prasad will be appointed prior to his return next month to the University of California, San Francisco, where he taught before joining the agency last year. Makary emphasized that Prasad accomplished a significant amount during his tenure at the FDA.

Prasad’s resignation follows heightened scrutiny of the FDA’s actions over the past year. The agency has denied or discouraged at least eight drug approval applications, citing concerns with the supporting data provided by the companies. Notably, the FDA initially refused to review Moderna’s flu vaccine but later altered its stance.

These decisions have sparked widespread criticism, with industry stakeholders asserting that the FDA has altered its guidance regarding acceptable evidence for applications. This has led to fears that an unreliable regulatory process may hinder the development of treatments for challenging diseases. A former FDA official, speaking anonymously, described the agency’s inconsistency as a dangerous form of regulatory uncertainty, as companies experience confusion regarding the criteria for approvals.

In response to these allegations, an FDA spokesperson announced that there was no regulatory uncertainty. The spokesperson asserted the agency’s commitment to making decisions based on evidence without guaranteeing specific outcomes, underscoring that the FDA conducts thorough, independent reviews rather than simply approving applications.

The most recent controversy involved the FDA discouraging UniQure from seeking expedited approval for its experimental Huntington’s disease treatment. This situation is part of a larger backlash against the FDA, which has undergone significant staff reductions and restructuring under Health and Human Services Secretary Robert F. Kennedy Jr. Critics worry that these changes could negatively impact the approval processes for new treatments, raising safety concerns for patients.

Criticism of Prasad intensified, particularly following an interview where Makary seemingly expressed disapproval of UniQure’s gene therapy. Although he did not mention the company directly, his comments fueled calls for accountability within the agency. The demand for a shakeup at the FDA was echoed even more strongly at a recent CNBC Cures event.

As the FDA faces scrutiny and recalibrates its approach to drug and vaccine approvals, Prasad’s departure signals a pivotal moment for the agency. Stakeholders and advocates alike will watch closely to see who steps into this crucial role and how future decisions will shape the landscape of drug development in the U.S.

This narrative underscores the ongoing evolution at the FDA as it navigates complex regulatory challenges and strives to maintain patient safety while fostering innovation in the biotech field.

Original Source: https://www.cnbc.com/2026/03/06/fda-vaccine-head-prasad-step-down.html
Category :
Tags:
Publish Date: 2026-03-07 23:34:00

Author

adminitfy

Follow Me
Other Articles
Kerala Lottery Results – 27 Feb 2026: Check Winning Numbers Now
Previous

Kerala Lottery Result Today — 7th March 2026: Check Winning Numbers

Meghalaya CM Grants Rs 2 Lakh to Sanfida Nongrum for AFC Debut Goal
Next

Meghalaya CM Grants Rs 2 Lakh to Sanfida Nongrum for AFC Debut Goal

Search...

Recent Posts

  • Dhubri Bar Election: Record 91% Turnout, Ahmed Elected President
    Dhubri Bar Election: Record 91% Turnout, Ahmed Elected President
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Dhubri Bar Election: Record 91% Turnout, Ahmed Elected President
  • Assam Fake Certificate Crackdown: 75+ Nagaon Schools File FIRs
  • Trump Orders Contractors to Seek White House Approval Before Congress
  • Manipur NIA Court Grants Bail to 8 KCP (PWG) Cadres; 2 Insurgents Held
  • The Next SaaS Moat Is Customer Workflow Mastery
  • November 2026 (685)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.